

Guanzhen GAO¹, Chizumi ABE¹, Alexia M. NECTOUX¹, Shu-Wei HUANG¹, Yuji MIYATA², Kazunari TANAKA³, Takashi TANAKA⁴, Haruo YAMAMURA⁵ and Toshiro MATSUI^{1*}

(¹Faculty of Agriculture, Kyushu University, ²Nagasaki Agricultural and Forestry Technical Development Center, ³University of Nagasaki, ⁴Graduate School of Biochemical Science, Nagasaki University, ⁵Charle Corporation, Ltd.)

Objectives: In previous study, we reported anti-hypertensive effect of a fermented Mikan tea containing hesperidin in mild hypertensive human study¹⁾, while the underlying mechanism remains unclear. Thus, in this study, the anti-hypertensive mechanism caused by the intake of Mikan tea was investigated using spontaneously hypertensive rats (SHRs).

Methods: Long-term (20 weeks) administration study of hesperidin (50 mg/kg/day) and Mikan tea (50 mg/kg/day) was performed in 8-week-old SHRs. Systolic blood pressure (SBP) and heart rate were measured biweekly. Vasomotor (relaxation/contraction) responses of the aorta taken after the protocol were examined. Levels of Vasomotor-related parameters (Ang II, Ang (1-7), NOx, cAMP) were measured in blood or aorta. Protein expression of AT₁R, AT₂R, and MasR in the aorta was evaluated by a Wes analysis.

Results: Daily intake of hesperidin or Mikan tea to SHRs resulted in a significant SBP reduction of approximately 60 mmHg. Vascular tension experiments revealed that the aorta in hesperidin and Mikan groups maintained potent contraction/vasorelaxation responses by 1 mM phenylephrine/100 μM acetylcholine stimulation, compared to control aorta. The aorta and blood taken from 28-wk SHRs also revealed that pressor Ang II and AT₁R, and depressor Ang (1-7), AT₂R, and NO levels were not influenced by hesperidin or Mikan tea intake, while MasR in the aorta was upregulated in hesperidin group. Along with an increasing aortic cAMP level in the group, it was speculated that the anti-hypertensive effect of hesperidin or Mikan tea was closely associated with the activation of vasorelaxation signaling via the MasR/cAMP axis.

1) Tanaka, K. et al. (2020). *Japanese Pharmacol. Ther.* **48**, 225–235.